Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Announces FDA Approval of New Steroid-Releasing Implant, Allowing More Chronic Sinusitis Patients to Benefit from Localized Drug Delivery
Toggle Summary Groundbreaking Clinical Evidence Demonstrates Benefit of PROPEL Implant for Chronic Sinusitis Patients
Toggle Summary Intersect ENT Quadruples Operation Size with Expansion to New Facility in Menlo Park, Calif.
Toggle Summary Intersect ENT Announces Positive Data from Pivotal Study of Propel Implant, Showing Significantly Improved Outcomes For Sinus Surgery
Toggle Summary Intersect ENT Announces U.S. Food and Drug Administration Approval for First Drug Releasing Implant for Chronic Sinusitis Patients
Toggle Summary Intersect ENT Closes Series C Financing, Recognized for Clinical Science
Toggle Summary Sinexus changes name to Intersect ENT, Initiates Pivotal Study
Toggle Summary Sinexus Welcomes New CEO and Completes Series B